/cloudfront-us-east-2.images.arcpublishing.com/reuters/G5JWOXLOQZIDLHFUUAR3HXPXEQ.jpg "Teva to pay $523 mln to New York as it looks to move past opioid lawsuits | Reuters")
Teva to pay $523 mln to New York as it looks to move past opioid lawsuits | Reuters
Israel's Teva, US Allergan agree to pay $54 million in San Francisco opioid lawsuit | The Times of Israel
Teva said to 'walk away' from settlement talks in US price-fixing lawsuit | The Times of Israel
Teva & Allergan Settle WV Opioid Lawsuit For Over $160 Million | MedTruth - Prescription Drug & Medical Device Safety | Informed Advocacy
New York Jury Finds Drugmaker Teva Liable for Fueling Opioid Crisis
Teva, Israel's Biggest Country, In Opioid Legal Trouble
Teva Pharmaceuticals, NY reach opioid lawsuit settlements worth $523M - Top Class Actions
Attorney General Morrisey sues opioid makers Johnson & Johnson, Teva Pharmaceuticals | WBOY.com
Teva to pay $54M to settle whistleblower lawsuit - Philadelphia Business Journal
Teva Pharmaceuticals will pay $420 million in a federal case
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Pharmaceutical Company Reaches Settlement With Oklahoma In Opioid Case : NPR
Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | Reuters
Texas settles another opioid lawsuit, wins $225 million against Teva
Teva agrees to $4.35B settlement to end opioid lawsuits - Top Class Actions
Teva to pay $512M to resolve Provigil-delay lawsuit
Teva drops lawsuit with Amicus over Creates Act dispute
Trouble at Teva: US price-fixing lawsuit adds to generic giant's woes - Pharma Technology Focus | Issue 85 | August 2019
Teva Pharmaceutical | PBS NewsHour
Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma
Teva Settles Price-Fixing-Related Securities Class Action Litigation for $420 Million | The D&O Diary
Allergan, Teva to pay $54M in San Francisco opioid lawsuit
California judge rules for Israeli Teva in major opioid lawsuit - The Jerusalem Post
EpiPen litigation comes back to haunt Teva
